FLT3 Inhibitor-Based Agricultural Pest Control Systems and Methods

Publication ID: 24-11857546_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “FLT3 Inhibitor-Based Agricultural Pest Control Systems and Methods,” Published Technical Disclosure No. 24-11857546_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857546_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,546.

Summary of the Inventive Concept

The present inventive concept relates to the application of crenolanib, or salts thereof, to control and monitor FLT3 mutated pest populations in agricultural settings, providing a novel approach to pest management and reducing the environmental impact of traditional pest control methods.

Background and Problem Solved

The original patent disclosed the use of crenolanib for treating FLT3 mutated proliferative disorders in humans. However, the problem of FLT3 mutated pest populations in agricultural settings remains unsolved. The present inventive concept addresses this limitation by applying the core technology of the original patent to a new field, providing a targeted and effective solution for pest control and monitoring.

Detailed Description of the Inventive Concept

The inventive concept comprises systems and methods for detecting and controlling FLT3 mutated pest populations using crenolanib or its pharmaceutically acceptable salts. The system includes a sensor for detecting FLT3 mutated pest populations and a dispenser for releasing a therapeutically effective amount of crenolanib to treat the pest populations. The method involves applying a composition comprising crenolanib to the crops and monitoring the crops for signs of pest infestation. Additionally, the inventive concept includes a device for detecting FLT3 mutated pests and a system for reducing the environmental impact of agricultural pest control.

Novelty and Inventive Step

The new claims are novel and non-obvious over the original patent as they apply the FLT3 inhibitor technology to a completely new field, agricultural pest control, and provide a targeted solution for controlling FLT3 mutated pest populations. The inventive concept's novelty lies in the unexpected application of crenolanib to agricultural pest control, which is not suggested by the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept include using different FLT3 inhibitors, varying the composition and dosage of crenolanib, and integrating the system with existing agricultural monitoring and control systems. Variations of the method include using different application methods, such as spraying or injection, and combining crenolanib with other pest control agents.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the agricultural industry, particularly in the areas of pest control and crop protection. The target market includes agricultural companies, farmers, and crop protection services. The inventive concept's environmental benefits and targeted approach to pest control make it an attractive solution for the agricultural industry.

Field of Art

Pharmaceutical and biotechnology research, specifically targeting kinase inhibitors and their potential applications in therapeutic and agricultural domains

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in molecular biology, pharmacology, or biochemistry, possessing expertise in kinase inhibition, drug repurposing, and cross-domain technology translation

Obviousness Rationale

A PHOSITA would recognize that the fundamental mechanism of FLT3 inhibition disclosed in the source patent could be readily adapted to alternative domains like pest control, given the structural similarities between cellular signaling pathways in human and agricultural systems. The technical principles of targeted molecular intervention are transferable across biological contexts, making the agricultural pest control application a predictable extension of the original therapeutic approach.

Obvious Combinations & Variations

Source Patent Element
Crenolanib as a targeted FLT3 tyrosine kinase inhibitor for treating hematological malignancies
PTD Variation
Applying crenolanib to control FLT3 mutated pest populations in agricultural settings
Obviousness Reasoning
Known technique of drug repurposing, where molecular mechanisms can be translated across biological systems with predictable results
Source Patent Element
Detection methods for identifying FLT3 mutations in human cells
PTD Variation
Developing sensors and detection systems for identifying FLT3 mutations in agricultural pest populations
Obviousness Reasoning
Predictable application of existing molecular detection technologies to a related biological detection problem
Source Patent Element
Dosage ranges for therapeutic administration of crenolanib (50-500 mg per day)
PTD Variation
Adapting dosage ranges for pest control applications with proportional scaling
Obviousness Reasoning
Routine optimization of known pharmaceutical formulation techniques for a related technological domain
Source Patent Element
Combination therapy approaches for treating resistant cellular populations
PTD Variation
Developing strategies to prevent resistance development in agricultural pest populations
Obviousness Reasoning
Analogous problem-solving approach using established molecular intervention principles
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857546, a person having ordinary skill in the art would find the agricultural pest control applications of crenolanib and associated detection methodologies to be obvious variations of the original therapeutic invention, thereby rendering potential claims in this domain anticipated and non-patentable under standard obviousness analysis.

Original Patent Information

Patent NumberUS 11,857,546
TitleCrenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment
Assignee(s)Arog Pharmaceuticals, Inc.